A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa

Cardiovascular Journal of Africa

Volumn 28, Issue 6, 2017, Pages 346-349

  Jacobs, Annemarie ^a   Decloedt, Eric H ^a   Bassa, Fatima ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Bleeding; Cost; Toxicity; Treatment; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CITALOPRAM; CLOPIDOGREL; COTRIMOXAZOLE; EFAVIRENZ; FLUOXETINE; METRONIDAZOLE; MIRTAZAPINE; MOXIFLOXACIN; SIMVASTATIN; VALPROIC ACID; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; REVIEW; SOUTH AFRICA; TERTIARY CARE CENTER; TREATMENT INDICATION; UNIVERSITY HOSPITAL; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG COST; DRUG EFFECT; DRUG INTERACTION; ECONOMICS; HOSPITAL COST; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MIDDLE AGED; MORTALITY; POLYPHARMACY; PRELIMINARY DATA; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; DRUG COSTS; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HOSPITAL COSTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MALE; MEDICATION ERRORS; MIDDLE AGED; POLYPHARMACY; PRELIMINARY DATA; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 85039715131     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2017-029     Document Type: Review

References (10)

1. Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med 2016; 8(1): a1032.
2. Rossiter D (ed). South African Medicines Formulary. Cape Town: Health and Medical Publishing Group of the South African Medical Association, 2014: 102–103.
3. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009; 30(7): 375–386.
4. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MM, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115(18): 3827–3834.
5. Westaway K, Cruickshank M, Roberts GW, Esterman AJ. Factors influencing over-anticoagulation and bleeding warfarin therapy during the initial five months of treatment. Austr Nursing J 2010; 17(10): 28–31.
6. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109: 481–485.
7. Hull RD, Garcia DA. Correcting excess anticoagulation after warfarin [Online] 2015 [access 2015, April 23]; Available: http://www.uptodate.com/contents/correcting-excess-anticoagulation-after-warfarin
8. Mezin J, Hoesche J, Friedman M, Nichols C, Bergman C, Crowther M, et al. Failure to correct international normalized ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. J Thromb Haemostasis 2012; 10: 596–605.
9. ®. Interactive Drug Interactions database (Truven Health Analytics Inc. Micromedex® Healthcare Series) 2016. [Online]. Available: http://www.micromedexsolutions.com/micromedex2/librarian/CS/C70D18/ND_PR/evidencexpert/ND_P/evidencexpert/ DUPLICATIONSHIELDSYNC/9DCF96/ND_PG/evidencexpert/ ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.FindDrugI [2016, July]
10. Primohamed M, Burnside G, Eriksson N, Jorgensen AL, Hock Toh C, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. New Engl J Med 2013; 369(24): 2294–2303.